- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Senate Panel Launches Investigation Into Pharmaceutical Pricing
The bipartisan panel has asked 4 drug makers, including Turing Pharmaceuticals, to submit documents to the US Senate's Special Committee on Aging.
Four companies—Valeant Pharmaceuticals, Turing Pharmaceuticals, Retrophin Inc, and Rodelis Therapeutics—have been reprimanded by the US Senate's Special Committee on Aging. This is a result of the unreasonable drug price hikes of generic drugs that had been acquired by these companies. Additionally, Democrats want to vote on issuing a subpeona to both Valeant and Turing Pharmaceuticals.
"We need to get to the bottom of why we're seeing huge spikes in drug prices that seemingly have no relationship to research and development costs," said Senator Claire McCaskill, D-Missouri, in a statement. She added that some of the increases resemble "little more than price gouging."
Read more on Reuters.
Study Suggests Adding BTKi to Chemo May Improve Early Outcomes in Richter Transformation in CLL
December 18th 2025The study suggests that adding a Bruton tyrosine kinase inhibitor (BTKi) to frontline chemoimmunotherapy in Richter transformation improved complete response rates and progression-free survival compared with chemoimmunotherapy alone, though overall survival benefits remained unclear.
Read More
